Alector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates

Reuters

08/08

<a href="https://laohu8.com/S/ALEC">Alector Inc.</a> Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates

Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation (FTD-GRN) expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease (AD), with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R Strategy and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557959118"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557959118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557959118?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557959118","market":"us","top_or_hot":-1,"title":"Alector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALEC\">Alector Inc.</a> Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation (FTD-GRN) expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease (AD), with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-08 05:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ALEC\">Alector Inc.</a> Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation (FTD-GRN) expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease (AD), with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALEC","symbol_name":"Alector Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL1z3XKd:1","article_id":"2557959118","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557959118","pubTimestamp":1754600438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation  expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease , with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R Strategy and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALEC":"Alector Inc.","BK4139":"生物科技"},"translate_title":"Alector Inc.推出有关脑部疾病治疗进展和临床计划更新的演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALEC":0.9},"content_text":"Alector Inc. Unveils Presentation on Advancements in Brain Disorder Treatments and Clinical Program Updates\n    \n\n        Alector Inc. has released a corporate presentation highlighting its strategic positioning in treating brain disorders. The presentation outlines Alector's progress in its late-stage clinical programs, including a pivotal Phase 3 data readout in frontotemporal dementia with a GRN gene mutation (FTD-GRN) expected by mid-Q4 2025 and the completion of Phase 2 clinical trial enrollment in Alzheimer's disease (AD), with trial completion anticipated in 2026. Alector continues to advance its innovative science with the 3R Strategy and advanced technologies focused on anti-Aβ antibody and GCase enzyme replacement therapies. The company remains well-resourced, with financial means extending into the second half of 2027 and a profit-sharing collaboration for PGRN product candidates. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}